Peptides in Immunity: A Guide to Antimicrobial and Signaling Roles

Researchers searching for the biological functions of immune peptides frequently encounter contradictory definitions. Some sources describe these molecules exclusively as natural antibiotics that destroy microbial membranes. Other texts group cytokines, chemokines, and major histocompatibility complex ligands together under the same functional label.

This guide provides a definitive reference for how peptides function across innate and adaptive immunity. It examines direct antimicrobial effectors, receptor-dependent signaling molecules, and antigen fragments displayed to T cells. By comparing their cellular sources, molecular targets, and structural mechanisms, this resource clarifies how distinct peptide families protect host tissues.

Functional Classifications in Peptide Immunology

The word peptide designates a specific molecular form rather than a uniform immune mechanism. Peptides are short chains of amino acid residues linked by peptide bonds. In immunology, this basic physical structure supports fundamentally distinct biological activities. Sorting these molecules into functional categories prevents confusion when reviewing experimental literature.

Immunological peptides divide into three primary categories based on how they interact with target systems. The first category comprises antimicrobial peptides, often termed host-defence peptides. These molecules function primarily as innate effectors that interact with microbial surfaces or modify early host inflammatory responses. The second category contains immune signaling peptides and small proteins, including chemokines, cytokines, and neuropeptides. These entities transmit regulatory instructions by binding specific surface receptors on host cells. The third category contains antigenic peptides, which are proteolytic fragments bound to major histocompatibility complex molecules for surveillance by T cells.

These functional divisions represent useful analytical distinctions rather than rigid boundaries. Certain host-defence peptides exert direct microbicidal activity while simultaneously engaging host receptors to recruit leukocytes. Similarly, specific neuropeptides demonstrate both neuroendocrine signaling capacity and direct antibacterial properties in vitro. Researchers must therefore analyze immune peptides by evaluating five criteria: cellular source, tissue compartment, molecular target, biochemical mechanism, and observed biological outcome.

A rigorous evaluation requires understanding compound identity and amino acid sequence analysis to prevent generalizing findings across unrelated peptide families. Chemical properties like net charge, hydrophobicity, and three-dimensional folding dictate whether a sequence acts as a physical disruptive agent or a high-affinity receptor ligand.

Structural Architecture and Direct Antimicrobial Mechanisms

Host-defence peptides are conserved molecular components of innate immunity found across animals, plants, and microorganisms. In humans, these molecules are primarily cationic and amphipathic. Cationic peptides maintain an overall positive charge at physiological pH due to an abundance of arginine and lysine residues. Amphipathicity allows the folded peptide to segregate its hydrophilic and hydrophobic residues onto opposing faces of the molecule.

This structural arrangement facilitates electrostatic attraction between the peptide and negatively charged components of microbial surfaces. Gram-negative bacterial outer envelopes contain anionic lipopolysaccharides, while Gram-positive cell walls contain negatively charged teichoic and lipoteichoic acids. In contrast, eukaryotic outer cell membranes consist predominantly of zwitterionic phospholipids with neutral net charges. This fundamental biochemical difference provides cationic peptides with intrinsic selectivity for microbial targets over host cell membranes.

Once electrostatic binding occurs, host-defence peptides employ several distinct physical mechanisms to compromise membrane integrity:

The Barrel-Stave Mechanism

Peptides insert perpendicularly into the lipid bilayer. Hydrophobic regions align with the interior lipid core, while hydrophilic surfaces face inward to form an organized, aqueous transmembrane pore.

The Toroidal Pore Mechanism

Inserted peptides induce local curvature in the lipid bilayer. The resulting pores consist of a composite structure lined by both peptide monomers and lipid phospholipid head groups.

The Carpet Model

Peptides accumulate horizontally across the outer membrane surface, covering it like a carpet. Once a threshold concentration is reached, the peptides exert a detergent-like effect that disrupts bilayer architecture without forming discreet protein channels.

Direct antimicrobial activity is not limited to pore formation or catastrophic membrane lysis. Research demonstrates that peptide interactions vary significantly depending on membrane lipid saturation. Investigations into LL-37 indicate that the peptide forms discreet pores in bilayers composed of unsaturated phospholipids. In bilayers composed of saturated phospholipids, however, LL-37 produces distinct membrane-modulating effects without stable pore formation.

Host-defence peptides can also cross bacterial envelopes to target internal machinery without causing immediate lysis. Some sequences inhibit bacterial protein synthesis, block enzymatic activity, or interfere with DNA and RNA replication. Furthermore, many peptides bind and neutralize bacterial products. LL-37 binds bacterial lipopolysaccharide directly, which reduces its capacity to stimulate toxic inflammatory cascades through host Toll-like receptors.

The Human Defensin Superfamily

Defensins represent one of the most thoroughly documented families of host-defence peptides in mammalian biology. They are small, cationic peptides containing six conserved cysteine residues that form three intramolecular disulfide bonds. These covalent crosslinks stabilize a compact beta-sheet core, conferring resistance against rapid proteolytic degradation within inflammatory environments.

The defensin superfamily comprises three distinct subfamilies based on disulfide connectivity: alpha-defensins, beta-defensins, and theta-defensins. Humans express six documented alpha-defensins and at least four characterized beta-defensins. More than 100 distinct defensin molecules have been reported across animal species. Theta-defensins exist as functional cyclic peptides in non-human primates, whereas human theta-defensin genes contain premature stop codons that prevent translation.

Human Alpha-Defensins

Human neutrophil peptides 1 through 4, designated HNP-1 to HNP-4, are stored in the primary azurophilic granules of neutrophils. They are released into phagosomes during phagocytosis or secreted extracellularly during acute activation. Human defensins 5 and 6, designated HD-5 and HD-6, are synthesized by specialized epithelial Paneth cells located in the crypts of the small intestine. HD-5 exhibits potent microbicidal activity, whereas HD-6 forms self-assembling nanonets that trap luminal pathogens physically rather than destroying them through membrane lysis.

Human Beta-Defensins

Human beta-defensins, designated hBD-1 through hBD-4, are synthesized primarily by epithelial cells lining the respiratory, gastrointestinal, and genitourinary tracts, as well as the skin. While hBD-1 is often expressed constitutively to maintain baseline barrier defense, hBD-2 and hBD-3 are strongly upregulated in response to proinflammatory cytokines or bacterial components. In addition to broad-spectrum microbicidal activity, human beta-defensins modulate adaptive immune recruitment. Specifically, hBD-2 and hBD-3 engage the chemokine receptor CCR6 to recruit immature dendritic cells and memory T cells to barrier surfaces.

Evaluating these dual roles requires grading evidence across experimental models to distinguish direct in vitro pathogen killing from complex receptor-mediated host recruitment. The concentrations required to kill bacteria in low-salt media often differ substantially from the lower physiological concentrations that trigger chemokine receptor migration in living tissues.

Cathelicidins and the Biology of Precursor Processing

Cathelicidins constitute a distinct family of host-defence peptides defined by a conserved N-terminal cathelin domain and a highly variable C-terminal antimicrobial domain. While several mammalian species express numerous cathelicidins, humans possess only one functional cathelicidin gene, designated CAMP. This gene encodes the precursor protein human cationic antimicrobial protein 18, commonly abbreviated as hCAP18.

The synthesis and activation of hCAP18 highlights an essential principle of peptide biology: precursor proteins and mature functional peptides are structurally and functionally distinct. The intact hCAP18 molecule lacks potent antimicrobial activity in its native state. Activation requires targeted enzymatic cleavage by specific host proteases, which liberates the biologically active 37-amino-acid C-terminal peptide known as LL-37.

Cleavage occurs in a compartmentalized manner governed by specific tissue environments:

Neutrophil Granules

Neutrophils synthesize hCAP18 and package it within secondary granules. Upon cellular activation and degranulation, proteinase 3 cleaves the pro-sequence to release active LL-37 into the extracellular milieu or phagolysosome.

Cutaneous Epithelium

In the epidermis, keratinocytes produce hCAP18 during barrier repair or infection. Proteolytic processing on the skin surface is mediated by kallikrein family serine proteases, which generate LL-37 alongside alternative truncated peptide fragments with unique activity profiles.

Seminal Fluid

Prostatic secretions contain high concentrations of hCAP18. Following ejaculation, gastricsin present in vaginal fluid processes the precursor at acidic pH into the 38-amino-acid antimicrobial peptide ALL-38.

The mature peptide LL-37 exhibits notable functional pleiotropy. Beyond broad-spectrum activity against bacteria, enveloped viruses, and fungi, LL-37 acts as a versatile signaling mediator. It promotes the chemotaxis of neutrophils, monocytes, and T cells by engaging host formyl peptide receptor-like 1. It influences the differentiation of dendritic cells, modulates angiogenesis, and accelerates re-epithelialization during tissue repair.

LL-37 also suppresses tissue damage during severe infection by binding circulating bacterial lipopolysaccharide. In murine septicemia models, exogenous LL-37 administration significantly protected against endotoxin-induced shock. However, this protective outcome represents an in vivo animal finding and cannot be assumed to translate directly into clinical efficacy for human sepsis.

Epithelial Barrier Defense and Compartmentalized Immune Responses

Epithelial barriers illustrate how host-defence peptides operate within complex physiological microenvironments. The mucosal lining of the human respiratory tract serves as an instructive model. In the lungs, immune protection depends on a delicate balance between rapid pathogen clearance and the preservation of gas exchange surfaces.

The respiratory compartment receives host-defence peptides from multiple cooperating cell types:

• Respiratory Epithelium & Macrophages
• Airway Surface Fluid
• Infiltrating Neutrophils

Respiratory epithelial cells constitutively secrete hBD-1 into the thin layer of airway surface fluid covering the cilia. Upon microbial exposure, these cells rapidly upregulate hBD-2 and hBD-3, while alveolar macrophages produce hCAP18. When local defenses are overwhelmed, infiltrating neutrophils extravasate into the airway space, releasing alpha-defensins and proteinase 3 to generate high local concentrations of LL-37.

Within this compartment, host-defence peptides perform diverse homeostatic tasks beyond pathogen lysis:

• Regulation of inflammatory cytokine secretion from respiratory epithelial cells.
• Promotion of epithelial migration and proliferation to repair wounded mucosa.
• Recruitment of immature dendritic cells and lymphocytes from underlying vascular beds.
• Maintenance of local protease and antiprotease equilibrium to protect fragile lung parenchyma.
• Modulation of redox homeostasis to mitigate oxidative injury during neutrophil bursts.

The airway microenvironment also illustrates why in vitro antimicrobial assays often fail to predict in vivo activity. Airway surface fluid contains physiological salt concentrations, mucins, and serum proteins that alter peptide behavior. Many defensins lose significant antibacterial potency in high-ionic-strength environments because ambient salt ions compete electrostatically for binding sites on bacterial membranes. Consequently, a peptide that appears potent in diluted laboratory broth may function primarily as a signaling or chemotactic molecule in living tissues.

Peptide Signaling Mediators in Leukocyte Coordination

Signaling peptides and small protein mediators organize the spatial and temporal recruitment of immune cells. Unlike host-defence peptides that physically disrupt structures or neutralize toxins, signaling mediators act through high-affinity, stereospecific binding to cell-surface receptors.

Cytokines represent a diverse category of small protein signaling agents produced by immune and structural cells. They include interleukins, interferons, and tumor necrosis factors, operating across picomolar to nanomolar concentrations. Binding to cognate receptors triggers intracellular cascades like the JAK-STAT pathway, altering gene expression in target leukocytes. Cytokine signaling exhibits extensive pleiotropy, where a single mediator produces multiple distinct cellular responses depending on the recipient cell type and local microenvironment.

Chemokines form a specialized chemotactic subclass within the broader cytokine superfamily. Structurally, chemokines are small proteins characterized by conserved cysteine motifs categorized into CC, CXC, CX3C, and C subfamilies. They direct leukocyte migration by establishing immobilized concentration gradients along extracellular matrix glycosaminoglycans. Circulating leukocytes recognize these chemical paths using surface G-protein-coupled receptors, driving directional extravasation toward inflamed tissues.

Understanding the difference between defensin recruitment and chemokine trafficking requires examining receptor binding dynamics versus biological outcomes. While chemokines evolved specifically for nanomolar receptor interaction, host-defence peptides often engage signaling receptors at micromolar concentrations. The following comparisons clarify their distinct functional profiles:

Primary Evolutionary Target

Chemokines target specific host G-protein-coupled receptors on target immune cells. Host-defence peptides evolved primarily to interact with anionic lipid surfaces on microbial envelopes.

Affinity and Operational Range

Chemokines operate at picomolar and nanomolar concentrations to establish long-range spatial gradients. Host-defence peptides require micromolar concentrations to exert direct microbicidal activity, though they can stimulate receptors at lower levels.

Structural Specialization

Chemokines utilize flexible loops and a conserved core to engage the binding pockets of specific chemokine receptors. Host-defence peptides rely on broad amphipathic alpha-helices or stabilized beta-sheet folds that lack strict receptor-binding sequence constraints.

Functional Redundancy

Chemokine networks exhibit extensive receptor-ligand promiscuity designed to orchestrate precise leukocyte subsets over time. Host-defence peptides provide broad-spectrum physical protection, with cellular recruitment acting as a secondary link to adaptive immunity.

Neuroimmune Cross-Talk: Neuropeptide Signaling

The immune system does not operate in isolation from physiological monitoring networks. Primary afferent nerve fibers innervate peripheral tissues, including the skin, respiratory tract, and gut mucosa, positioning them near resident immune cells. Through the release of neuropeptides, the nervous system regulates immune responses, leukocyte migration, and vascular tone.

Neuropeptides are small proteinaceous signaling molecules secreted by neurons and neuroendocrine cells. Key neuropeptides involved in immune regulation include substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide. Receptors for these mediators are expressed broadly across macrophages, dendritic cells, mast cells, and T lymphocytes.

• Sensory Nerve Terminals
• Substance P (SP) NK1R Engagement Mast Cell Degranulation & Vasodilation
• Calcitonin Gene-Related RAMP1/CLR Murine T-Cell IL-2 Suppression
• Peptide (CGRP)
• Vasoactive Intestinal VPAC1/VPAC2 Macrophage Cytokine Reprogramming
• Peptide (VIP)

The biological outcomes of neuropeptide signaling are highly context-dependent:

Substance P

Substance P binds the neurokinin-1 receptor, commonly designated NK1R. In peripheral tissues, it stimulates mast cell degranulation, promotes vasodilation, and recruits granulocytes. It is broadly characterized as a proinflammatory mediator during early tissue injury, yet it also accelerates re-epithelialization during late-stage wound repair.

Calcitonin Gene-Related Peptide

Calcitonin gene-related peptide, abbreviated as CGRP, acts through a heterodimeric receptor complex composed of the calcitonin receptor-like receptor and receptor activity-modifying protein 1. CGRP is a potent microvascular vasodilator. In immune contexts, it frequently dampens antigen presentation. In murine experimental models, CGRP directly suppressed interleukin-2 production and inhibited proliferation in isolated murine T cells.

Vasoactive Intestinal Peptide

Vasoactive intestinal peptide, designated VIP, interacts with the G-protein-coupled receptors VPAC1 and VPAC2. VIP signaling generally suppresses the production of proinflammatory mediators like TNF-alpha and IL-12 in activated macrophages. Concurrently, it supports the generation and maintenance of regulatory T cells, helping protect barrier mucosal tissues from excessive inflammatory damage.

Some neuropeptides exhibit direct antibacterial properties against common pathogens in vitro. However, researchers must not classify all neuropeptides as antimicrobial agents. Their primary physiological role in living mammals is modulating cell behavior through specific receptor-mediated signaling pathways.

Antigenic Peptides and Major Histocompatibility Complex Presentation

Antigenic peptides represent an entirely separate functional category from antimicrobial effectors and soluble signaling ligands. Rather than killing pathogens or binding surface receptors, antigenic peptides serve as structural ligands presented on major histocompatibility complex molecules. This presentation allows alpha-beta T-cell receptors to inspect internal and external cellular proteomes.

T cells cannot recognize native, intact pathogen proteins in solution. Instead, protein antigens must be processed into short linear peptide fragments through intracellular proteolytic pathways. These fragments are loaded into the binding groove of MHC molecules and exported to the plasma membrane. T-cell activation requires specific dual recognition: the T-cell receptor must bind both the antigenic peptide and the surrounding alpha-helices of the host MHC molecule.

• Intracellular Proteins Extracellular Antigens
• v (Proteasomal Cleavage) v (Endosomal Proteolysis)
• Short Peptides (8-10 aa) Longer Peptides (10-25 aa)
• v (TAP Translocation) v (HLA-DM Catalysis)
• MHC Class I
• MHC Class II
• v (Surface Presentation) v (Surface Presentation)
• CD8 Cytotoxic T Cells CD4 Helper T Cells

Antigen presentation operates through two primary classical pathways:

The MHC Class I Pathway

MHC class I molecules are expressed on virtually all nucleated cells. They present peptides derived from endogenous intracellular proteins, such as self-proteins, viral products, or mutated tumor antigens. Intracellular antigens are degraded in the cytosol by the proteasome and transported into the endoplasmic reticulum via the transporter associated with antigen processing. Peptides bound by MHC class I typically range from 8 to 10 amino acid residues in length. The closed binding groove of the class I molecule anchors both the N- and C-termini, imposing strict length constraints. These complexes are recognized by CD8+ cytotoxic T cells.

The MHC Class II Pathway

MHC class II molecules are restricted to professional antigen-presenting cells, including dendritic cells, macrophages, and B lymphocytes. They present peptides derived from exogenous antigens internalized through endocytosis or phagocytosis. Following uptake, antigens are degraded by acidic proteases within endolysosomal compartments. The resulting peptides are loaded onto class II molecules with the assistance of the chaperone HLA-DM. Peptides presented by MHC class II are typically longer, ranging from 10 to 25 amino acid residues. Because the class II binding groove is open at both ends, peptide termini can extend outward, accommodating longer chains. These complexes are recognized by CD4+ helper T cells.

A vital exception to this compartmental division is cross-presentation. Professional antigen-presenting cells, especially conventional type 1 dendritic cells, can route internalized exogenous antigens into the cytosolic MHC class I pathway. This allows naive CD8+ T cells to mount cytotoxic responses against viral infections or tumors that do not directly infect the presenting dendritic cell.

Antigenic peptides are not bactericidal agents. They function as informational fragments that enable adaptive immune surveillance. Treating them as antimicrobial peptides obscures the specialized biochemical machinery that governs their generation and presentation.

Translational Barriers and Clinical Development Challenges

The broad-spectrum activity of host-defence peptides in vitro led researchers to investigate synthetic analogs as prospective alternatives to conventional antibiotics. Because their biophysical mechanism targets fundamental membrane structures, many hypothesized that microbes would struggle to develop resistance. Decades of translational research have revealed significant clinical hurdles that challenge these initial assumptions.

The path from in vitro antimicrobial potency to clinical efficacy faces several physiological obstacles:

• In Vitro Screening
• Potent killing in low-salt, protein-free broth
• Physiological Salt Inhibition Inactivation at 150 mM NaCl
• Serum Protein Binding High-affinity albumin sequestration
• Proteolytic Cleavage Rapid degradation by host/bacterial proteases
• In Vivo Failure
• Loss of microbicidal activity at target tissue site

In vitro screening is frequently conducted in low-salt, protein-free nutrient broth. When tested under physiological conditions, many natural peptides lose their microbicidal activity. Normal physiological concentrations of sodium, calcium, and magnesium compete electrostatically with cationic peptides for binding sites on bacterial membranes. Furthermore, circulating serum proteins like albumin bind hydrophobic surfaces on peptides, drastically reducing free active concentrations. Systemic administration often leads to rapid enzymatic cleavage by circulating proteases, resulting in half-lives measured in minutes.

Clinical trials evaluating host-defence peptide analogs provide clear examples of these translational challenges:

Pexiganan

Pexiganan is a 22-amino-acid synthetic analog of magainin-2, an antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. Developed as a topical cream for infected diabetic foot ulcers, pexiganan underwent two major phase III clinical trials enrolling 835 patients, using oral ofloxacin as a comparator. Both treatments achieved clinical cure or improvement in approximately 90% of patients. However, pathogen eradication at the end of therapy was lower for topical pexiganan at 66%, compared to 82% for oral ofloxacin. Subsequent trials failed to demonstrate superiority or sufficient non-inferiority to gain regulatory approval.

Omiganan

Omiganan is a synthetic peptide derivative of indolicidin, a natural cathelicidin isolated from bovine neutrophils. Formulated as a topical gel, omiganan was evaluated in clinical trials to prevent catheter-associated infections and treat severe acne vulgaris. Despite promising early-phase microbiological data, large phase III clinical trials failed to meet primary efficacy endpoints, demonstrating no statistically significant reduction in catheter-related bloodstream infections compared to standard antiseptic preparations.

The belief that bacteria cannot evolve resistance to host-defence peptides is incorrect. While resistance does not typically develop through single-point target mutations, microbes utilize several defensive adaptations:

• Alteration of cell-surface net charge via the addition of positively charged D-alanine to teichoic acids or 4-amino-4-deoxy-L-arabinose to lipid A, electrostatically repelling cationic peptides.
• Secretion of extracellular proteases, such as aureolysin or elastase, that degrade peptides before they reach the plasma membrane.
• Upregulation of active efflux pumps that recognize and expel amphipathic peptide molecules from the cell envelope.
• Release of anionic decoy molecules that bind and sequester host-defence peptides in the extracellular space.

For these reasons, scientists must avoid the high translational risk of mistaking preclinical peptide signals for human clinical proof. Preclinical data cannot substitute for well-controlled, randomized clinical trials that verify safety and efficacy in humans.

Analytical Methods and Documentation in Peptide Research

Interpreting experimental peptide literature requires rigorous scrutiny of the materials used in laboratory studies. Chemical synthesis of short peptides often produces truncated sequences, deletion fragments, and chemical side products. If research fails to verify the identity and purity of synthesized peptides, observed biological outcomes may stem from synthetic contaminants rather than the intended sequence.

High-performance liquid chromatography and mass spectrometry serve as foundational analytical tools in peptide research:

• Synthesized Peptide Sample
• Reverse-Phase HPLC Quantifies purity percentage via retention peaks
• Mass Spectrometry Confirms molecular weight and sequence identity

Reverse-phase HPLC separates peptides based on hydrophobicity, providing a purity percentage profile based on relative peak areas. Mass spectrometry establishes the absolute molecular weight of the primary compound, ensuring that the synthesized sequence matches its expected chemical formula.

Researchers evaluating laboratory records and purity verification methods must recognize the inherent limitations of these analytical methods. A certificate of analysis showing 98% purity verifies only that the specific analyzed sample met that analytical standard. It does not guarantee the stability of the compound in cell culture media, its resistance to proteolysis, or its behavior in the presence of serum proteins.

A certificate of analysis cannot establish biological sterility or the absence of endotoxins. Bacterial endotoxins are potent inflammatory stimulants that survive standard peptide synthesis protocols. If an antimicrobial peptide preparation is contaminated with trace levels of endotoxin, in vitro experiments assessing cytokine release or immune activation may measure host responses to the contaminant rather than the peptide itself. Rigorous studies must confirm that test peptides are free of endotoxin before drawing conclusions about immune modulation.

Systematic Evaluation Checklist for Research Literature

When reviewing publications on peptides in immunity, apply this systematic evaluation checklist to determine the scope and validity of reported findings:

1. Identify the functional category. Determine whether the study examines a direct antimicrobial effector, a receptor-binding signaling mediator, or an MHC-displayed antigenic ligand.
2. Confirm the exact chemical sequence. Verify that the research provides the primary amino acid sequence, Net charge, and structural modifications rather than ambiguous commercial designations.
3. Inspect analytical verification data. Check whether purity and molecular weight were confirmed using mass spectrometry and high-performance liquid chromatography.
4. Distinguish precursor proteins from cleaved peptides. Note whether the study investigates a full-length pro-protein or an enzymatically processed mature fragment.
5. Evaluate the testing environment. Determine whether antimicrobial assays were performed in simplified low-salt media or under physiological conditions with salt and serum proteins.
6. Check for endotoxin controls. Verify that studies claiming immune-modulatory or cytokine-inducing effects rigorously excluded endotoxin contamination.
7. Note the experimental model. Separate findings derived from cell-free liposome systems, in vitro cell cultures, animal challenge models, and human clinical trials.
8. Scrutinize mechanistic assertions. Confirm whether reported membrane disruption was directly visualized or whether alternative intracellular targets were explored.
9. Assess resistance claims. Evaluate whether assertions regarding antimicrobial resistance are supported by multi-passage selection experiments or merely assumed from mechanism.
10. Check clinical translation endpoints. Distinguish in vitro pathogen inhibition from demonstrated clinical cure rates in properly controlled trials.

By applying these criteria, researchers can accurately place individual studies within the broader landscape of peptide immunology, avoiding the common pitfalls of overgeneralization and uncritical translation.

Sources

1. A Review of Antimicrobial Peptides and Their Therapeutic ...
2. Defensins
3. Epithelial antimicrobial peptides in host defense against ...
4. Human defensins and LL-37 in mucosal immunity - Oxford Academic
5. REVIEW ARTICLE Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents β-defensins, cathelicidin LL-37 and lysozyme
6. Review: Defensins and cathelicidins in lung immunity
7. Introduction to Cytokine and Chemokine Networks - Springer
8. Neuroimmune regulatory networks of the airway mucosa in allergic inflammatory disease
9. The role of cellular and molecular neuroimmune crosstalk in gut immunity - Cellular & Molecular Immunology
10. Defensins and LL-37: A review of function in the gingival epithelium
11. Antimicrobial resistance: a concise update